ADMA Biologics, Inc. announced that the U.S. Food and Drug Administration has issued a Department of Health and Human Services U.S. license No. 2019 to the company in connection with the approval of ASCENIV Immune Globulin Intravenous, Human – slra 10% Liquid. The license covers the Boca Raton, FL manufacturing facility which has demonstrated compliance with FDA requirements as well as authorizes ADMA to manufacture and enter into interstate commerce with ASCENIV.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.